Eli Lilly & Co. (LLY) Tops Q3 EPS by 7c; Offers FY22 EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. CRWD
4. RXRX
5. ON
6. VRTX
7. INSP
8. CVI
9. CHKP
10. MPC

Go back to Eli Lilly & Co. (LLY) Tops Q3 EPS by 7c; Offers FY22 EPS Guidance

Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress

November 1, 2022 6:25 AM EDT

Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and lower Alimta revenue following the entry of generics. Total worldwide volume in Q3 2022 increased 14%. Strong launch for Mounjaro led to $97.3 million in U.S. revenue in Q3 2022. The company also recognized $86.0 million in Mounjaro revenue related to a sales collaboration agreement for the right to sell and distribute Mounjaro in Japan.Pipeline advancements included the FDA granting Fast Track... More